Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia.

McIntyre RS, Trakas K, Lin D, Balshaw R, Hwang P, Robinson K, Eggleston A.

Can J Psychiatry. 2003 Nov;48(10):689-94.

PMID:
14674052
2.

A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine.

Newcomer JW, Campos JA, Marcus RN, Breder C, Berman RM, Kerselaers W, L'italien GJ, Nys M, Carson WH, McQuade RD.

J Clin Psychiatry. 2008 Jul;69(7):1046-56.

PMID:
18605811
3.

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A.

Aust N Z J Psychiatry. 2007 Dec;41(12):980-9.

PMID:
17999270
4.

Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.

Dossenbach M, Erol A, el Mahfoud Kessaci M, Shaheen MO, Sunbol MM, Boland J, Hodge A, O'Halloran RA, Bitter I; IC-SOHO Study Group.

J Clin Psychiatry. 2004 Mar;65(3):312-21.

PMID:
15096069
6.

Impact of race on efficacy and safety during treatment with olanzapine in schizophrenia, schizophreniform or schizoaffective disorder.

Stauffer VL, Sniadecki JL, Piezer KW, Gatz J, Kollack-Walker S, Hoffmann VP, Conley R, Durell T.

BMC Psychiatry. 2010 Nov 3;10:89. doi: 10.1186/1471-244X-10-89.

7.

Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.

Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT.

J Clin Psychiatry. 2001 Sep;62(9):694-700.

PMID:
11681765
8.

A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.

McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH.

J Clin Psychiatry. 2004;65 Suppl 18:47-56.

PMID:
15600384
10.
11.

Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.

Bobes J, Rejas J, Garcia-Garcia M, Rico-Villademoros F, García-Portilla MP, Fernández I, Hernández G; EIRE Study Group.

Schizophr Res. 2003 Jul 1;62(1-2):77-88.

PMID:
12765747
12.

Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.

Dossenbach M, Pecenak J, Szulc A, Irimia V, Anders M, Logozar-Perkovic D, Peciukaitiene D, Kotler M, Smulevich AB, West TM, Lowry AJ, Treuer T.

J Clin Psychiatry. 2008 Dec;69(12):1901-15. Epub 2008 Sep 9.

PMID:
19012820
13.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
14.

Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study.

Treuer T, Hoffmann VP, Chen AK, Irimia V, Ocampo M, Wang G, Singh P, Holt S.

World J Biol Psychiatry. 2009;10(4 Pt 3):729-40. doi: 10.1080/15622970903079507.

PMID:
19606406
15.

Treatment with olanzapine, risperidone or typical antipsychotic drugs in Asian patients with schizophrenia.

Lee C, Wu KH, Habil H, Dyachkova Y, Lee P.

Aust N Z J Psychiatry. 2006 May;40(5):437-45.

PMID:
16683970
16.
17.

Quetiapine versus other atypical antipsychotics for schizophrenia.

Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S.

Cochrane Database Syst Rev. 2013 Nov 18;(11):CD006625. doi: 10.1002/14651858.CD006625.pub3. Review.

PMID:
24249315
18.

Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.

Fraguas D, Merchán-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giráldez M, Arango C.

J Clin Psychiatry. 2008 Jul;69(7):1166-75.

PMID:
18588363
19.

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

J Clin Psychiatry. 2003 May;64(5):598-604.

PMID:
12755665
20.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947

Supplemental Content

Support Center